Dren Bio Reaches Agreement with Sanofi for $1.9 Billion Acquisition
Deal News | Mar 20, 2025 | Goodwin
Sanofi, a global pharmaceutical leader, has entered into a definitive agreement to acquire DR-0201, a CD20-directed bispecific antibody developed by Dren Bio. DR-0201, targeting myeloid cells for deep B-cell depletion, is part of Dren Bio's innovative pipeline in treating cancer and autoimmune diseases. The acquisition involves the takeover of Dren Bio's affiliate, Dren-0201, and is valued at up to $1.9 billion, which includes a $600 million upfront payment and $1.3 billion in contingent milestone payments. The transaction is expected to close in Q2 2025, pending regulatory approvals. Goodwin Procter LLP advised Dren Bio on this transaction, instrumental in drafting and guiding through various contractual and legal dimensions essential for a landmark acquisition in the life sciences sector.
Sectors
- Biopharmaceutical
- Pharmaceutical
- Legal Advisory
Geography
- United States – Dren Bio is a US-based company and the transaction is subject to US regulatory approvals.
- France – Sanofi is headquartered in France, playing a significant role in the acquisition.
Industry
- Biopharmaceutical – Dren Bio is a clinical-stage biopharmaceutical company focusing on novel antibody therapeutics for cancer and autoimmune diseases.
- Pharmaceutical – Sanofi, a major player in the pharmaceutical sector, is acquiring a new therapeutic candidate from Dren Bio to enhance its treatment capabilities.
- Legal Advisory – Goodwin provided legal advisory services for the acquisition, dealing with regulatory, corporate, and other essential legal aspects.
Financials
- $600 million – Upfront payment by Sanofi for acquiring Dren-0201.
- $1.3 billion – Potential milestone payments contingent upon development and launch achievements.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Dren Bio | Target Company | Company | A clinical-stage biopharmaceutical company pioneering first-in-class antibody therapeutics. |
| Sanofi | Bidding Company | Company | A leading global healthcare company involved in the acquisition of Dren Bio's affiliate. |
| Goodwin | Legal Advisor | Company | Provided comprehensive legal services to Dren Bio for the acquisition transaction. |